A randomised double blind placebo controlled trial of infusional subcutaneous octreotide in the management of malignant bowel obstruction at the end of life.
Ontology highlight
ABSTRACT: Interventions: A phase III randomised, double blind, placebo controlled trial of octreotide (600mcg) delivered by continuous subcutaneous infusion used in conjunction with bolus daily parenteral (subcutaneous or intravenous) dexamethasone (8mg), ranitidine (200mg per 24 hours, either as bolus or continuous subcutaneous infusion) and parenteral hydration (continous subcutaneous or intravenous infusion) of(10mls/kg/24hours) over a maximum of 72 hours.
Primary outcome(s): The primary outcome is number of days without an episode of vomiting in the first 72 hours of the study.[72 hours from the start of treatment]
Study Design: Purpose: Treatment; Allocation: Randomised controlled trial; Masking: Blinded (masking used);Assignment: Parallel;Type of endpoint: Efficacy
DISEASE(S): Bowel Obstruction In The Setting Of Advanced Cancer,Cancer-other Cancer Types
PROVIDER: 2453927 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA